Regulation of Biotechnology Intellectual Property Protection in China

1. Introduction

China’s biotechnology intellectual property (IP) framework protects inventions involving genetic engineering, pharmaceuticals, vaccines, industrial biotechnology, microorganisms, diagnostic technologies, and biological manufacturing. The principal objective is to encourage scientific innovation while balancing public health, research freedom, environmental protection, and access to essential medicines.

Biotechnology IP protection in China is governed primarily by the Patent Law of the People’s Republic of China, alongside regulations on patent implementation, trade secrets, trademarks, copyright, and genetic-resource management. The legal framework also interacts with pharmaceutical regulatory requirements and rules governing human genetic resources.

A central feature of Chinese law is that not every biological discovery is patentable. Patent protection generally requires a qualifying invention that satisfies novelty, inventiveness, and practical applicability, together with the applicable disclosure requirements.

2. Principal legal framework

A. Patent Law of China

The Patent Law, amended most recently in 2020 and effective in its revised form from 1 June 2021, is the principal statute governing biotechnology inventions.

Article 2 distinguishes inventions, utility models, and designs. Biotechnology inventions generally fall within the invention-patent category because they concern products, processes, or improvements involving technical solutions.

Article 22 establishes the principal patentability requirements:

Novelty: The invention must not form part of the prior art.

Inventiveness: The invention must demonstrate a sufficiently substantive improvement over prior art.

Practical applicability: The invention must be capable of being made or used and produce beneficial results.

Article 25 excludes specified subject matter from patent protection, including scientific discoveries and methods for the diagnosis or treatment of diseases. These exclusions require careful interpretation in biotechnology because a biological discovery may be unpatentable as such, whereas a technically developed product or process based on that discovery may qualify.

For example, discovering that a naturally occurring microorganism produces a particular enzyme does not automatically create a patentable invention. A genetically engineered microorganism with a specifically modified pathway, a novel production method, or a technically improved enzyme formulation may be patentable if all statutory requirements are satisfied.

B. Implementing Regulations and Examination Guidelines

The Implementing Regulations of the Patent Law and the China National Intellectual Property Administration’s (CNIPA) Patent Examination Guidelines provide further rules for examining biotechnology applications.

They are particularly important for inventions involving:

DNA, RNA, proteins, and engineered biological sequences;

isolated or modified microorganisms;

recombinant vectors and genetically engineered cells;

vaccines, antibodies, and therapeutic proteins;

fermentation processes and biological manufacturing.

Patent applications must disclose the invention sufficiently for a skilled person to implement it. Where biological material cannot adequately be described in writing, deposit requirements may apply under the relevant rules.

C. Genetic-resource requirements

China’s patent framework also addresses inventions relying on genetic resources. Article 26 of the Patent Law requires disclosure of the direct and original source of genetic resources where the invention relies on them. If the applicant cannot identify the original source, the reasons must be stated.

Article 5 also restricts patent rights for inventions or creations completed in violation of laws or administrative regulations or contrary to social morality or the public interest. In addition, the Biosecurity Law and the Regulation on the Administration of Human Genetic Resources establish separate controls over certain biological research and genetic-resource activities.

These rules are particularly relevant to biotechnology companies developing products from human-derived samples, indigenous biological materials, or biological resources obtained through international research collaborations.

3. Patent protection for different biotechnology inventions

4. Important judicial decisions

Case 1: Monoclonal antibody binding-molecule patent case (2019)

Court: Supreme People's Court Intellectual Property Court.

The dispute concerned a patent application entitled “Binding Molecules” relating to monoclonal antibody technology. The patent authority had rejected the application on inventive-step grounds, and the applicant challenged the rejection through administrative review and litigation.

The Supreme People's Court upheld the first-instance judgment requiring the patent authority to reconsider its decision. The proceedings emphasized the importance of appropriately evaluating the creativity involved in biotechnology inventions rather than underestimating their technical contribution.

Supreme People's Court

+1

Legal significance: The case illustrates that antibody-related inventions must be assessed in light of their actual technical features and inventive contribution. The mere fact that an invention concerns an established biotechnology field does not resolve whether it is obvious.

Case 2: Non-invasive prenatal diagnosis patent case (2022)

Case number: (2022) Zui Gao Fa Zhi Xing Zhong No. 811.

This dispute concerned a patent application titled Diagnosis of Fetal Chromosomal Aneuploidy Using Genome Sequencing. The invention used biological samples, such as maternal plasma, and large-scale parallel genome sequencing to diagnose fetal chromosomal abnormalities.

The patent authority had rejected the application for lack of inventiveness, and the lower court dismissed the applicant's challenge. The applicant appealed to the Supreme People's Court. The case was subsequently identified by the Court among its typical cases concerning protection of scientific innovation.

中华人民共和国最高人民法院

Legal significance: The case highlights the importance of examining the specific technical contribution of genomic diagnostic inventions. It also demonstrates the distinction between potentially patentable technical products or systems and diagnostic methods excluded by Article 25. The case should not be interpreted as establishing that every genomic diagnostic method is patentable.

Case 3: Enzalutamide patent validity dispute (2022)

Case number: (2022) Zui Gao Fa Zhi Xing Zhong No. 287.

The dispute involved a patent for diaryl hydantoin compounds associated with enzalutamide. The patent authority had declared the patent invalid. The first-instance court overturned that decision, after which the parties appealed.

The Supreme People's Court upheld the first-instance outcome. It accepted supplementary experimental data used to substantiate technical effects already disclosed in the original patent specification. The Court also considered the sensitivity of the structure–activity relationship and the unpredictability of the relevant technical effects when evaluating inventive step.

中华人民共和国最高人民法院

Legal significance: Supplementary experimental evidence may support patentability when it confirms an effect disclosed in the original application. It cannot ordinarily be used to repair an inherent disclosure deficiency by introducing a technical effect absent from the original specification.

Case 4: Engineered microorganism patent disclosure dispute (2024)

Case number: (2024) Zui Gao Fa Zhi Xing Zhong No. 1241.

In this patent invalidation dispute, the invention concerned an engineered Sphingomonas strain, its construction, and its applications. The Supreme People's Court explained in its April 2026 case summary that an engineered microorganism produced through gene overexpression may satisfy the sufficient-disclosure requirement when the specification enables skilled persons to reproduce the microorganism and reasonably understand its expected technical effects.

最高人民法院知识产权法庭

+1

Legal significance: Biotechnology patents require technically adequate disclosure, but the law does not necessarily demand exhaustive experimental proof of every conceivable result. The decisive question is whether the disclosed information enables implementation and supports the claimed technical solution.

Case 5: Cordyceps sinensis gene patent infringement appeal (2026)

On 23 April 2026, the Supreme People's Court publicly heard an appeal concerning a patent for an enzyme and gene associated with adenosine-related biosynthesis in Cordyceps sinensis. The central dispute involved whether the accused manufacturers' fermentation and production activities fell within the scope of a patent defined by a particular amino-acid sequence.

The first-instance court had rejected the infringement claims, reasoning that the defendants had not implemented the patented technical solution at the genetic-engineering level. The Supreme People's Court identified the proper construction of the patent claims and comparison with the accused technology as central issues. The cited report describes the hearing, not a final appellate judgment.

中华人民共和国最高人民法院

Legal significance: A patented gene sequence does not automatically confer exclusive rights over every downstream product containing material associated with that organism. Infringement depends on the actual claims, their proper interpretation, and the technical features of the accused process or product.

5. Trade secrets and confidential biotechnology know-how

Not all biotechnology innovations should be protected through patents. The Anti-Unfair Competition Law protects qualifying technical information that is not generally known, has commercial value, and is subject to appropriate confidentiality measures.

Trade-secret protection can cover:

Fermentation conditions and production parameters.

Cell-line development protocols.

Manufacturing yields and purification techniques.

Unpublished experimental data and proprietary research methods.

Unlike patents, trade secrets do not require public disclosure. However, they do not prevent lawful independent development or use of information that becomes public without a legally actionable breach.

Companies should use confidentiality agreements, controlled laboratory access, employee invention agreements, and documented information-security measures to strengthen their claims.

6. Ownership, licensing, and enforcement

Biotechnology ownership disputes may arise between universities, researchers, pharmaceutical companies, contract research organisations, and manufacturers.

Written agreements should clearly allocate ownership of background IP, newly developed inventions, research data, patent-filing responsibilities, and licensing income.

Patent holders may seek injunctions and compensation for infringement under Chinese law. Patent disputes can involve complex scientific evidence, expert opinions, and comparisons between claimed sequences, engineered organisms, and commercial production processes.

7. Conclusion

China's biotechnology IP framework combines patent protection, trade-secret law, specialized genetic-resource requirements, and judicial enforcement. The cases discussed above demonstrate four recurring principles: genuine inventive contribution matters; disclosure must enable reproduction; experimental evidence must support rather than reconstruct the original application; and infringement depends on the actual scope of patent claims.

For biotechnology businesses operating in China, effective protection therefore requires not only filing patents but also documenting research, preserving confidential know-how, verifying genetic-resource compliance, and drafting claims that accurately reflect the invention's technical contribution.